演題抄録

FACO International Workshop

開催概要
開催回
第53回・2015年・京都
 

Circulating tumor cells early predict prognosis of hepatocellular carcinoma treated with transarterial chemoembolization: A prospective study

演題番号 : FWS4-4

[筆頭演者]
Zhou Bo:1 
[共同演者]
Yang Guowei:1、Wang Jianhua:1、Liu Rong:1

1:Intervention Oncology, Intervention Radiology, Fudan University Zhongshan Hospital

 

Backgroud To evaluate the potential utility of circulating tumor cells (CTCs) measurements in predicting prognosis of hepatocellular carcinoma (HCC) patients received transarterial chemoembolization (TACE) treatments, including their differences in different vein sites and the immediate and delayed impact of TACE on CTCs.
Methods CTCs from consecutive patients with HCC were quantified before and immediately and 6-8 weeks after TACE. CTCs were examined in both samples derived from the peripheral vein (PV) and the hepatic vein (HV).
Results A total of 46 consecutive patients with HCC were recruited into the prospective study and 38 were analysed at last. CTCs counts in HV were significantly higher than in PV (P<0.001). TACE led to a statistically significant immediate fall in CTCs numbers, especially in HV(P<0.001). Patients with CTCs levels >=2 in PV or >=8 in HV at baseline per 7.5 ml blood samples, compared with the group with fewer CTCs in PV or HV, had a shorter median progression-free survival (PFS, 5.2 months vs. 12.0 months, P=0.01; 5.2 months versus 9.5 months, P=0.003, respectively). At the 6-8 weeks after TACE, patients with CTCs >=2 in PV or >=3 in HV had a similarly shorter PFS (5.0 months vs. 12.0 months, P<0.001; 5.1 months versus 11.2 months, P<0.001, respectively). Further analysis showed that patients with higher CTC levels also had a higher intrahepatic metastasis rate. The multivariate Cox regression analyses and ROC curves showed that the levels of CTCs at baseline and 6-8 weeks after TACE were significant independent prognostic factors of PFS.
Conclusions The number of CTCs in peripheral and hepatic vein before and 6-8 weeks after TACE are independent predictors of PFS in HCC patients received TACE treatments. TACE immediately reduces the number of CTCs get into the blood circulation.

キーワード

臓器別:Liver

手法別:Clinical Trial

前へ戻る